Advanced

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease

Mattsson, Niklas LU ; Schöll, Michael LU ; Strandberg, Olof LU ; Smith, Ruben LU ; Palmqvist, Sebastian LU ; Insel, Philip S. LU ; Hägerström, Douglas LU ; Ohlsson, Tomas; Zetterberg, Henrik LU and Jögi, Jonas LU , et al. (2017) In EMBO Molecular Medicine 9. p.1212-1223
Abstract

To elucidate the relationship between cerebrospinal fluid (CSF) total-tau (T-tau) and phosphorylated tau (P-tau) with the tau PET ligand 18F-AV-1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T-tau and P-tau were highly correlated (R = 0.92, P < 0.001), but they were only moderately associated with retention of 18F-AV-1451, and mainly in demented AD patients. 18F-AV-1451, but not CSF T-tau or P-tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal 18F-AV-1451 retention. However, not all dementia AD patients exhibited... (More)

To elucidate the relationship between cerebrospinal fluid (CSF) total-tau (T-tau) and phosphorylated tau (P-tau) with the tau PET ligand 18F-AV-1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T-tau and P-tau were highly correlated (R = 0.92, P < 0.001), but they were only moderately associated with retention of 18F-AV-1451, and mainly in demented AD patients. 18F-AV-1451, but not CSF T-tau or P-tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal 18F-AV-1451 retention. However, not all dementia AD patients exhibited increased CSF tau, even though 18F-AV-1451 retention was always increased at this disease stage. We conclude that CSF T-tau and P-tau mainly behave as biomarkers of "disease state", since they appear to be increased in many cases of AD at all disease stages, already before the emergence of tau aggregates. In contrast, 18F-AV-1451 is a biomarker of "disease stage", since it is increased in clinical stages of the disease, and is associated with brain atrophy and cognitive decline.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer, Biomarker, Cerebrospinal fluid, Positron emission tomography, Tau
in
EMBO Molecular Medicine
volume
9
pages
1212 - 1223
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • scopus:85026306368
ISSN
1757-4676
DOI
10.15252/emmm.201707809
language
English
LU publication?
yes
id
fb5c7d65-d0a4-4cab-a439-e127aad7b318
date added to LUP
2017-09-01 15:26:12
date last changed
2017-09-02 03:00:03
@article{fb5c7d65-d0a4-4cab-a439-e127aad7b318,
  abstract     = {<p>To elucidate the relationship between cerebrospinal fluid (CSF) total-tau (T-tau) and phosphorylated tau (P-tau) with the tau PET ligand <sup>18</sup>F-AV-1451 in Alzheimer's disease (AD), we examined 30 cognitively healthy elderly (15 with preclinical AD), 14 prodromal AD, and 39 AD dementia patients. CSF T-tau and P-tau were highly correlated (R = 0.92, P &lt; 0.001), but they were only moderately associated with retention of <sup>18</sup>F-AV-1451, and mainly in demented AD patients. <sup>18</sup>F-AV-1451, but not CSF T-tau or P-tau, was strongly associated with atrophy and cognitive impairment. CSF tau was increased in preclinical AD, despite normal <sup>18</sup>F-AV-1451 retention. However, not all dementia AD patients exhibited increased CSF tau, even though <sup>18</sup>F-AV-1451 retention was always increased at this disease stage. We conclude that CSF T-tau and P-tau mainly behave as biomarkers of "disease state", since they appear to be increased in many cases of AD at all disease stages, already before the emergence of tau aggregates. In contrast, <sup>18</sup>F-AV-1451 is a biomarker of "disease stage", since it is increased in clinical stages of the disease, and is associated with brain atrophy and cognitive decline.</p>},
  author       = {Mattsson, Niklas and Schöll, Michael and Strandberg, Olof and Smith, Ruben and Palmqvist, Sebastian and Insel, Philip S. and Hägerström, Douglas and Ohlsson, Tomas and Zetterberg, Henrik and Jögi, Jonas and Blennow, Kaj and Hansson, Oskar},
  issn         = {1757-4676},
  keyword      = {Alzheimer,Biomarker,Cerebrospinal fluid,Positron emission tomography,Tau},
  language     = {eng},
  pages        = {1212--1223},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {EMBO Molecular Medicine},
  title        = {<sup>18</sup>F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease},
  url          = {http://dx.doi.org/10.15252/emmm.201707809},
  volume       = {9},
  year         = {2017},
}